Only two per cent of child drug trials have independent safety checksMarch 19, 2008Only two per cent of paediatric drug trials reported using independent safety monitoring committees that can help lead to the early detection of adverse drug reactions, according to a major review published in the journal Acta Paediatrica. Child health researchers from The University of Nottingham carried out a detailed analysis of 739 international drug trials published between 1996 and 2002, to see what safety measures were in place to monitor levels of adverse drug reactions. While 74 per cent of the drug trials described how safety monitoring was performed during the study, only two per cent - 13 studies out of 739 - had independent safety monitoring committees.
Lead author Dr Helen Sammons, an Associate Professor of Child Health in the University's Academic Division of Child Health, based at Derbyshire Children's Hospital, said: "We were very surprised by the low level of trials that had independent safety monitoring committees and are urging pharmaceutical companies to include these in all future trials involving children. "It is essential that drugs are developed for use in children and clinical trials need to continue. They are vital because they increase the chance of picking up adverse reactions before drugs are introduced into general clinical practice." Dr Sammons and her colleagues found that: · Seven out of ten trials reported adverse events and a fifth of the trials reported a serious adverse event, ie. an untoward medical occurrence, not necessarily related to a drug. · Adverse drug reactions were reported in just under 37 per cent of trials, with 11 per cent of trials reporting moderate or severe adverse drug reactions. · Six clinical trials - which all had safety monitoring committees - were terminated early because of significant drug toxicity. · Deaths were reported in 11 per cent of the trials, but the majority were thought to be unrelated to the drug use. · Death rates were highest in trials involving newborn babies, with 56 per cent of the 99 trials included reporting a death. · Other major specialities in which deaths were reported included infectious diseases, neurology, respiratory and kidney problems. Only papers published in English on the Medline database during the seven-year study period were included and the authors excluded studies that covered HIV and cancer because of high deaths rates from the actual diseases. Just over half of the studies compared a drug with a placebo - dummy - and a further 35 per cent involved a new medicine. A smaller percentage, 26 per cent, involved a direct comparison between two established drugs. Some of the trials included adults as well as children. Studies reporting severe drug toxicity problems came from a wide range of countries, including Argentina, Belgium, Canada, Chile, China, France, India, Israel, Italy, Japan, Netherlands, South Africa, Sweden, Taiwan, Thailand, Turkey, UK and the USA. Adverse drug reactions included bleeding, high blood pressure, seizures, psychosis, suicide, acute renal failure and death. The researchers stress that clinical drug trials in children are essential for the development of medicines and to provide evidence of the best treatments for specific conditions. But they feel that greater safety measures and awareness of the risk is essential. "We need to test drugs on children as the only other options are to use unlicensed drugs or prescribe drugs that have been licensed for adults off-label - outside the terms of their licence," said Dr Sammons. "But we feel that the small number of studies that reported having safety monitoring committees was unacceptable. It is invaluable to have an independent monitor who can swiftly question any adverse drug reactions or differences in illness and death rates between groups taking part in the clinical trials. "Parents also need to be made aware of the risks of adverse drug reactions when a child takes any medicine so that they can make informed decisions that balance those risks against the possible benefits the drug may provide their child. "In a drug trial this should include information on the mechanisms that will be used during the clinical trial to safeguard the children taking part." Dr Sammons points out that the number of paediatric drug trials is likely to rise in the European Union, following new legislation that provides pharmaceutical companies with a valuable financial incentive - a six-month extension to their exclusive manufacturing licence for a drug if children are included in the clinical trials. Similar legislation has been in place in the USA for over five years and has led to an increase in drug trials that include children. She added: "There is general agreement by paediatric health professionals, regulatory authorities and the pharmaceutical industry, as well as politicians and parents, that drug trials are essential in order to improve drug therapies. "We are calling for all paediatric drug trials to include independent safety monitoring committees to ensure that this vital work is carried out in a way that minimises risks, and maximises benefits, for the children taking part." The University of Nottingham | |||||||||||||||||||||
|
Related Drug Trials News Articles Family therapy helps relieve depression symptoms in bipolar teens Family-focused therapy, when combined with medication, appears effective in stabilizing symptoms of depression among teens with bipolar disorder, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals. PET scans may help assess presence of brain plaques related to Alzheimer's disease A type of positron emission tomography (PET) scanning may be useful in a non-invasive assessment of the formation of Alzheimer's disease-related plaques in the brain, according to small study posted online today that will appear in the October 2008 print issue of Archives of Neurology, one of the JAMA/Archives journals. Personalized therapy for asthma and COPD could soon be here Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease. Sensor necklace aims to increase elderly and clinical trial participant drug compliance Researchers now have a possible solution for the one in three adults who fail to take their medicines as prescribed by their doctors, as well as for everyone else who occasionally forgets: a sensor necklace that records the exact time and date when specially-designed pills are swallowed, and reminds the user if any doses are being missed. Computers could be used to diagnose Alzheimer's disease Computers are able to diagnose Alzheimer's disease faster and more accurately than experts, according to research published in the journal Brain. The findings may help ensure that patients are diagnosed earlier, increasing treatment options. Value of drugs for pre-osteoporosis exaggerated A series of recent scientific publications have exaggerated the benefits and underplayed the harms of drugs to treat pre-osteoporosis or "osteopenia" potentially encouraging treatment in millions of low risk women, warn experts in this week's BMJ. New strategy to cut heart attack risk is effective in initial test The first clinical trial of a new kind of drug to cut the risk of cardiovascular disease has been found safe and effective at dropping levels of "bad" low density lipoprotein (LDL) cholesterol by as much as 40 percent. FDA petition would protect public from dangerous drugs In a petition filed today with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist. MRI predicts liver fibrosis, study says Moderate to severe chronic liver disease can be predicted with the use of diffusion-weighted MRI (DWI), according to a recent study conducted by researchers at New York University Medical Center in New York, NY. Key to out-of-control immune response in lung injury found Researchers at the University of Illinois at Chicago College of Medicine have discovered how a protein modulates the inflammatory response in sudden, life-threatening lung failure. The protein's previously unknown role is reported in the August issue of Nature Medicine. More Drug Trials News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||